Loading
companiesCompany
Acrivon Therapeutics
Acrivon Therapeutics uses a protein-activity test to pick the patients most likely to respond to its cancer drugs. Its lead drug blocks DNA damage checkpoint proteins and is being tested in womb and ovarian cancer.
Overview
Acrivon Therapeutics is a Watertown, Massachusetts clinical-stage company that pairs its AP3 (Acrivon Predictive Precision Proteomics) phosphoproteomics platform with drug candidates targeting DNA damage response and cell cycle regulation. Its lead programme, ACR-368 (prexasertib, in-licensed from Lilly), is a CHK1/CHK2 inhibitor with single-agent activity including complete responses in platinum-resistant ovarian and squamous cell cancers; the company uses its OncoSignature assay to select patients, holds FDA Fast Track designation for OncoSignature-selected endometrial and platinum-resistant ovarian cancer, and Breakthrough Device designations for the assay. ACR-2316, a dual WEE1/PKMYT1 inhibitor, is in the clinic, and ACR-6840 targets CDK11 in IND-enabling studies. Acrivon completed its Nasdaq IPO in November 2022.
Headquarters
Watertown, MA, US
Funding
All startupsPublic
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · IPO closed 17 November 2022 with a concurrent 5 million US dollar private placement to Chione; gross IPO proceeds not stated in the fetched filing | 2022 | undisclosed | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · ACRV
Stage
Public
Website
Notes
top- IPO gross proceeds not captured from the fetched 8-K or prospectus excerpt, so the amount is omitted. Founding year not sourced.
Similar pages
- CompanyNonagen Bioscience
Shares Proteomics & phosphoproteomics, Companion diagnostics.
- CompanyZentalis Pharmaceuticals
Shares WEE1, Ovarian cancer, Small-molecule kinase inhibitors.
- CompanyOncoHost
Shares Proteomics & phosphoproteomics, Companion diagnostics.
- TreatmentAzenosertib
Shares WEE1, Ovarian cancer.
- IdeaA commons for leftover trial biospecimens with standard access for approved research
Shares Proteomics & phosphoproteomics, Companion diagnostics.
- CompanyDebiopharm
Shares WEE1, Ovarian cancer.
- TreatmentBRACAnalysis CDx
Shares Companion diagnostics, Ovarian cancer.
- CompanyMyriad Genetics
Shares Companion diagnostics, Ovarian cancer.